



DEPARTMENT OF  
**Neurology**

# Acute Stroke Research

*Ethical considerations*



**Justin A. Sattin, MD**

*Professor of Neurology*

*Vice Chair for Education*

*Residency Program Director*

*UW Department of Neurology*

**UW** [Health](#) *Comprehensive Stroke Program*

# Outline

- Background
- Decisional Capacity
- Surrogate Decision-Making
- Exceptions from Informed Consent
  - Clinical context
  - Research context
- Conclusion




# Background

## *Outdated thinking*

- “[R]esearch arguably does not need specific rules for self-regulation because it is, by definition, an activity that routinely monitors itself.”







Bernhard Walther or Ernst Hofmann or Karl-Friedrich Höcker,  
Public domain, via Wikimedia Commons



Alexander Voronzow and others in his group, ordered by  
Mikhael Oschurkow, head of the photography unit,  
Public domain, via Wikimedia Commons




# Research Misconduct in the U.S.




<https://www.openaccessgovernment.org/modernising-healthcare-nuclear-way/13031/>

Works Progress Administration poster, Public Domain,  
<https://commons.wikimedia.org/w/index.php?curid=1953647>



# (Alleged) Research Misconduct in the U.S.



# Nuremberg Code (1947) Declaration of Helsinki (1964)

- The voluntary consent of the human subject is absolutely essential.
- The experiment should be such as to yield fruitful results for the good of society, unprocurable by other methods . . .

Rudolf Brandt, defendant in the Doctors' Trial. OMGUS Military Tribunal,  
Public domain, via Wikimedia Commons



# Congressional Action (1974)

- Dept. of Health, Education, and Welfare mandated to clarify rules.
- Created a National Commission for the Protection of Human Subjects

## **THE BELMONT REPORT**

Office of the Secretary

Ethical Principles and Guidelines for the Protection of Human  
Subjects of Research

The National Commission for the Protection of Human Subjects of  
Biomedical and Behavioral Research

April 18, 1979



# Congressional Action (1991)

- 45 CFR § 46
  - Subpart A (“Common Rule”)
  - Subpart B: Pregnant women, fetuses, and neonates
  - Subpart C: Prisoners
  - Subpart D: Children



# IRB Role

- Risks to subjects are minimized
- Risks are reasonable in relation to anticipated benefits
- Selection of subjects is equitable
- Informed consent will be sought from each prospective subject or the subject's legally authorized representative
- Informed consent will be appropriately documented;
- The research plan makes adequate provision for monitoring the data.
- There are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.



# When is IRB Approval Required?

- *Human subjects*: Direct interaction or use of identifiable data.
- *Research*: A “systematic investigation . . . designed to develop or contribute to generalizable knowledge”





# Outline

- Background
- Decisional Capacity
- Surrogate Decision-Making
- Exceptions from Informed Consent
  - Clinical context
  - Research context
- Conclusion



# Ethical Principles

- Autonomy (respect for persons)
- Beneficence
- (Non-maleficence)
- Justice

## **THE BELMONT REPORT**

Office of the Secretary

Ethical Principles and Guidelines for the Protection of Human  
Subjects of Research

The National Commission for the Protection of Human Subjects of  
Biomedical and Behavioral Research

April 18, 1979

[https://www.hhs.gov/ohrp/sites/default/files/the-belmont-report-508c\\_FINAL.pdf](https://www.hhs.gov/ohrp/sites/default/files/the-belmont-report-508c_FINAL.pdf)



DEPARTMENT OF  
**Neurology**

# Moral Implications of Autonomy

- Tell the truth
- Respect privacy
- Protect confidential information
- Obtain consent for interventions





# Autonomy → Informed Consent

- Disclosure of relevant information
- Recommendation of a plan
- Patient consent (or refusal)
  - In the absence of coercion
  - In a patient with decisional capacity



Autonomy →  
Informed Consent →  
Decisional Capacity

- Understanding
- Appreciation
- Reasoning
- Choice

Appelbaum PS, Grisso T. Assessing patients' capacities to consent to treatment.  
N Engl J Med. 1988;319(25):1635-1638.



DEPARTMENT OF  
Neurology

# Understanding


- A grasp of the basic facts surrounding a decision:
  - The medical condition
  - Proposed intervention
  - Risks
  - Benefits
  - Alternatives





# Understanding

- May be assessed via the “teach-back” method.
- May be impaired, e.g., by Wernicke’s aphasia.



Autonomy →  
Informed Consent →  
Decisional Capacity

- Understanding
- Appreciation
- Reasoning
- Choice



# Appreciation


- How the provided information applies to one's own case.
- May be assessed by asking the patient for explanation of why a proposed course of action will or will not benefit them.





# Appreciation

- May be impaired in right hemispheric lesions that lead to hemineglect and anosagnosia.



Autonomy →  
Informed Consent →  
Decisional Capacity

- Understanding
- Appreciation
- Reasoning
- Choice




# Reasoning

- The ability to compare options and consistently infer the consequences of one's choices.
- May be assessed by asking patients how each of the available options will affect their daily lives.



# Reasoning

- May be impaired in the setting of prefrontal or parietal lobe injuries.
- Especially with respect to quantitative and probabilistic risks.





Autonomy →  
Informed Consent →  
Decisional Capacity

- Understanding
- Appreciation
- Reasoning
- Choice




# Choice

- Expressing a decision.
- Should be reasonably stable in the absence of new information.




# Choice

- Ability to express a choice may be impaired in:
  - Broca's aphasia
  - Reduced consciousness



# Assessing Decisional Capacity



# Assessing Decisional Capacity

UCSD Brief Assessment of Capacity to Consent (UBACC)	
1. What is the purpose of the study that was just described to you?	
Response (2 = Study investigational drug for memory)	Score
	0
	1
	2
2. What makes you want to consider participating in this study?	
Response (2 = Improve memory and attention, help others)	Score
	0
	1
	2
3. Do you believe this is primarily research or primarily treatment?	
Response (2 = Research)	Score
	0
	1
	2
4. Do you have to be in this study if you do not want to participate?	
Response (2 = No)	Score
	0
	1
	2

Jeste DV, Palmer BW, Appelbaum PS, et al. A New Brief Instrument for Assessing Decisional Capacity for Clinical Research. Arch Gen Psychiatry. 2007;64(8):966–974.





# Decisional Capacity

## *Review*

- Understanding
- Appreciation
- Reasoning
- Choice



# Outline

- Background
- Decisional Capacity
- Surrogate Decision-Making
- Exceptions from Informed Consent
  - Clinical context
  - Research context
- Conclusion



# Surrogate Decision-Making

- Guardian (of the person)
- Advance directives
  - Instruction directives
  - Proxy directives
- Next of kin
- Implications for clinical research



# Guardianship in WI

- *Clinical*: May withhold or withdraw life-sustaining treatment *only* in cases of chronic vegetative state.
- *Research*: May not provide research consent for wards being treated for mental illness, developmental disabilities, or alcohol or other drug dependencies.



# Surrogate Decision-Making

- Guardian (of the person)
- Advance directives
  - Instruction directives
  - Proxy directives
- Next of kin
- Implications for clinical research





# Instruction Directives

## *“Living wills”*

- Often too specific, referring only to feeding tubes or CPR, but not stroke treatments.
- Often too vague, referring to “terminal conditions”, but not clearly stroke.
- May, but usually don’t, mention research



# Proxy Directives

*HCPOA, DPOAHC*

- Surrogates should consider
  - Expressed wishes of the patient
  - Substituted judgement
  - Best interests (*harder to invoke in the research context*)
- POAs for research exist but are uncommon



# Surrogate Decision-Making

- Guardian (of the person)
- Advance directives
  - Instruction directives
  - Proxy directives
- Next of kin
- Implications for clinical research



# Next of Kin

- Laws vary by state.
- WI does not specify a hierarchy; individual hospitals often do.  
At UW:
  - Court-appointed guardian
  - HCPOA
  - Patient-identified surrogate (verbal or writing)
  - Spouse
  - Adult child(ren)
  - Parents
  - Siblings
  - Close relative or friend



# Surrogate Decision-Making

- Guardian (of the person)
- Advance directives
  - Instruction directives
  - Proxy directives
- Next of kin
- Implications for clinical research





# Surrogate Consent for Research


## *NINDS rt-PA example*

- 70% of 624 subjects were enrolled via surrogate consent.
- Study would otherwise have taken 12.5 years to complete (instead of 3.8).
- Self-consenting subjects were younger and had milder strokes.



# Surrogate Consent for Research

## *IST-3 example*



Kane I, Lindley R, Lewis S, Sandercock P; IST-3 Collaborative Group. Impact of stroke syndrome and stroke severity on the process of consent in the Third International Stroke Trial. *Cerebrovasc Dis.* 2006;21(5-6):348-52.

# Surrogate Consent for Research

*Federal Common Rule is broad*

- *Legally Authorized Representative*: An “individual . . . authorized under applicable law to consent on behalf of a prospective subject . . .”



# Surrogate Consent for Research

*State laws vary and are often silent*

- In WI, for example, surrogate consent is prohibited for mental health research (only).



# Surrogate Consent for Research

*Local IRB policies vary*

- At UW-Madison, research using surrogate consent must:
  - Be minimal risk; or
  - **Hold out the prospect for direct benefit; or**
  - Subjects must have signed an advance directive noting that they want to participate in such research.



# Surrogate Decision-Making

## *Review*

- Guardian (of the person)
- Advance directives
  - Instruction directives
  - Proxy directives
- Next of kin
- Implications for clinical research





# Outline

- Background
- Decisional Capacity
- Surrogate Decision-Making
- Exceptions from Informed Consent
  - Clinical context
  - Research context
- Conclusion




# Varieties of Consent

- Expressed
- Implicit / implied
- Tacit
- (Assent)
- Presumed



# Presumption of Consent


*Ethical considerations*



# Presumption of Consent

## *Case 1*


- IV alteplase in a patient presenting < 3 hours with severe deficits and no known contraindications.



# Presumption of Consent

## *Case 2*


- Thrombectomy of an M3 clot in a patient presenting  $> 24$  hours with moderate deficits.



# Presumption of Consent

## *Case 3*

- Decompressive hemicraniectomy in an unrepresented 70 year old patient with malignant LMCA infarct.



Consider  
ethics consult



# Presumption of Consent

## *General approach*

- “Standard of care” treatments should be applied.
- The further from standard, the more caution should be exercised in presuming consent.
- If time permits, consider ethics or legal services consultation.



# Outline

- Background
- Decisional Capacity
- Surrogate Decision-Making
- Exceptions from Informed Consent
  - Clinical context
  - Research context
- Conclusion



# Exceptions from Informed Consent

## *Literature review of justifications*

- Decreased data validity and quality
- Distress or confusion of participants
- Practical problems (e.g., time constraints)
- Ethical concerns



# Exceptions from Informed Consent

## *Minimal risk studies*

- IRB may alter or waive consent requirements for minimal risk studies:
  - May be applicable to systems-level interventions.
  - Also, e.g., telephone screening pre-enrollment.
  - Not applicable to reperfusion / neuroprotective therapies.



# Exceptions from Informed Consent

## *EFIC pathway*

- For research on emergency treatments for life-threatening, incapacitating, conditions.  
**Requirements include:**
  - Community consultation during planning
  - Public disclosure (before) and reporting (after)
  - Attempt to contact LAR for written consent, if feasible
  - Attempt to contact family, who may object
  - Patient refusal must be honored
  - Subject / surrogate later informed & may withdraw
  - Independent DMC

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exception-informed-consent-requirements-emergency-research>

Bateman BT, Meyers PM, Schumacher HC, et al. Conducting stroke research with an exception from the requirement for informed consent. *Stroke*. 2003 May;34(5):1317-23.



# Exceptions from Informed Consent

## *Systematic review of the EFIC pathway*

### EXHIBIT 1

#### Key characteristics of exception from informed consent (EFIC) trials involving new drugs or devices, 1996–2017

Characteristic	Trials (N = 41)	
	Number	Percent
<b>CONDITION TREATED</b>		
Cardiac arrest	16	39
Traumatic shock	11	27
Traumatic brain injury	6	15
Status epilepticus	3	7
Respiratory failure	2	5
Ischemic stroke	2	5
Acute coronary syndrome	1	2



# Exceptions from Informed Consent

*The justice principle as regards EFIC*

- Demographic data suggest the need to include more African Americans in the community consultation process.



# Exceptions from Informed Consent

*EFIC pathway in StrokeNet*



# Exceptions from Informed Consent

## *Deferred consent*

- Study procedures commence without consent.
- Once decisional capacity is regained, or a proxy identified, consent must be obtained for study continuation.
- Otherwise, subject may have to be withdrawn.



# Exceptions from Informed Consent

## *2-Stage pathway: TICH-2*

	All	2-stage doctor	2-stage patient	2-stage relative	1-stage patient	1-stage relative	P value
CT to random (min)	75	55	55	69	75	90	< 0.001
Onset to random ≤ 3 hrs.	36%	53%	44%	40%	33%	30%	< 0.001


Law ZK, Appleton JP, Scutt P, et al. Brief Consent Methods Enable Rapid Enrollment in Acute Stroke Trial: Results From the TICH-2 Randomized Controlled Trial. *Stroke*. 2022 Apr;53(4):1141-1148.



DEPARTMENT OF  
Neurology

# Do Waivers Increase Enrollment?

*Probably yes, for systems-level research*



Rose DZ, Kasner SE. Informed consent: the rate-limiting step in acute stroke trials. *Front Neurol.* 2011 Oct 17;2:65.


Feldman WB, Kim AS, Josephson SA, Lowenstein DH, Chiong W. Effect of waivers of consent on recruitment in acute stroke trials: A systematic review. *Neurology.* 2016;86(16):1543-1551.



DEPARTMENT OF  
Neurology

# Do Waivers Increase Enrollment?

*Possibly not in ED settings*



Rose DZ, Kasner SE. Informed consent: the rate-limiting step in acute stroke trials. *Front Neurol.* 2011 Oct 17;2:65.

Feldman WB, Kim AS, Josephson SA, Lowenstein DH, Chiong W. Effect of waivers of consent on recruitment in acute stroke trials: A systematic review. *Neurology.* 2016;86(16):1543-1551.






# Outline

- Background
- Decisional Capacity
- Surrogate Decision-Making
- Exceptions from Informed Consent
  - Clinical context
  - Research context
- Conclusion



# Consent Matrix

*Clinical paradigm*



# Consent Matrix


*Simple research paradigm*

	Minimal Risk	> Minimal Risk
Has Capacity	Written Consent (or waiver)	Written Consent
Lacks Capacity	Waiver	Surrogate Consent (or EFIC)



# Consent Matrix

*Flexible research paradigm*





DEPARTMENT OF  
Neurology

# Comments & Questions!

*See chat box for link to bibliography*

sattin@neurology.wisc.edu

